February 19, 2019 - The case was dismissed.
November 13, 2018 - A motion to dismiss the amended complaint was filed.
October 22, 2018 - An amended complaint was filed.
May 7, 2018 - An investor in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) filed a lawsuit in the U.S. District Court for the Eastern District of Michigan over alleged violations of Federal Securities Laws by Esperion Therapeutics, Inc. in connection with certain allegedly false and misleading statements made between February 22, 2017 and May 1, 2018.
Ann Arbor, MI based Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
According to the complaint the plaintiff alleges on behalf of purchasers of Esperion Therapeutics, Inc. (NASDAQ: ESPR) common shares between February 22, 2017 and May 1, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 22, 2017 and May 1, 2018, the defendants made false and/or misleading statements and/or failed to disclose that Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death, and that as a result of the foregoing, Esperion’s public statements were materially false and misleading at all relevant times
On May 2, 2018, Esperion Therapeutics, Inc announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion Therapeutics, Inc reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group.
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) declined to $33.06 per share on May 3, 2018.